NOX and US Govt Peak Cancer Agency Announce Collaboration
Filed with ASX · · 4 pages · English
Earlier from Noxopharm
- Veyonda Survival Advantage in LuPSMA Therapy Confirmed
- June 2021 Quarterly Activities Report and Appendix 4C
- DARRT-2 Study Receives IND Approval from FDA
- Noxopharm Secures Key European Patent Allowance for Veyonda
- DARRT-2 Study Update and Clarification
Later from Noxopharm
- Noxopharm: Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer
- NOXCOVID Program to Expand After Positive Phase 1 Results
- Pre-clinical Data Supports a Role for Veyonda in COVID-19
- Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
- Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm